John Wiley & Sons

John Wiley & Sons

Publishes scientific, technical, and medical literature

Overview

John Wiley & Sons publishes scholarly, professional, and educational content across science, technology, medicine, and the humanities. Its products include textbooks, journals, reference works, and digital resources delivered through the Wiley Online Library and other platforms. Wiley works with authors, editors, and peer reviewers to produce content, then distributes it via print, digital subscriptions, licensing, and open-access options to libraries, universities, researchers, and professionals. The company differentiates itself through a long history as a family-run business spanning six generations, a strategic shift from general printing to science and professional publishing, and a global scale as a publicly traded leader in educational and professional resources. Its goal is to provide reliable, accessible resources that support education, research, and professional development worldwide.

About John Wiley & Sons

Simplify's Rating
Why John Wiley & Sons is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Education

Healthcare

Company Size

51-200

Company Stage

IPO

Headquarters

Hoboken, New Jersey

Founded

1807

Get referred to John Wiley & Sons

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2027 research revenue rose 4%, with publishing up 12% and submissions up 31%.
  • Wiley booked $14 million AI revenue in Q1 2027 and contracted another $14 million.
  • Emerald added $5 million EBITDA in Q1 2027, ahead of schedule, with $30 million synergies.

What critics are saying

  • Learning revenue fell 20% in Q1 2027, exposing weak academic and professional demand.
  • The July 2026 False Claims Act suit targets Wiley over inflated open-access article fees.
  • Emerald’s $450 million acquisition lifted net debt to EBITDA to 2.7x after Q1 2027.

What makes John Wiley & Sons unique

  • Wiley’s 1807 scientific publishing brand still anchors trusted research distribution across STEM societies.
  • Its 71-partner AI Knowledge Nexus monetizes proprietary journals, data, and society relationships.
  • The September 3, 2026 Genesis Mission seat uniquely embeds Wiley inside DOE research infrastructure.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$230k

Above

Industry Average

Funded Over

1 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Remote Work Options

Hybrid Work Options

Professional Development Budget

Stock Price

Company News

Yahoo Finance
Sep 3rd, 2026
Wiley Q1 revenue declines on $29M AI licensing comparison, maintains $50M full-year AI target

John Wiley & Sons reported a first-quarter 2027 loss of $0.23 per share, driven by restructuring charges and costs from its $450 million Emerald acquisition. The publisher's net debt to EBITDA rose to 2.7 times following the deal. The company's research publishing division showed strength, with submission levels up 31%. Management expects full-year AI revenue to exceed $50 million, with recurring AI revenue growing two to three times over the prior year. The quarter's revenue declined year-over-year, primarily due to a $29 million prior-year AI licensing comparison and weakness in professional learning. However, Wiley's Emerald acquisition is performing ahead of schedule, contributing to margin expansion through early cost synergies. The company raised its dividend for the 33rd consecutive year whilst maintaining mid-single-digit growth expectations for research publishing.

MarketBeat
Sep 3rd, 2026
John Wiley & Sons Q1 earnings call highlights.

John Wiley & Sons Q1 earnings call highlights. September 3, 2026 Key points. * Research publishing and AI offerings drove growth: Research publishing revenue rose 12%, while Wiley generated $14 million in AI revenue and expanded partnerships and licensing agreements. However, results faced a $29 million prior-year AI licensing comparison. * Emerald integration is progressing ahead of schedule: The acquisition contributed $13 million in publishing revenue and $5 million in adjusted EBITDA, with Wiley targeting $30 million in annual cost synergies by the third year. * Learning remained weak, but full-year guidance was reaffirmed: Learning revenue fell 20% and adjusted EBITDA margins declined sharply amid softer academic and professional demand. Wiley maintained its fiscal 2027 outlook for low-to-mid-single-digit organic revenue growth, adjusted EPS of $4.60-$5.05, and $205 million in free cash flow. * Five stocks to consider instead of John Wiley & Sons. John Wiley & Sons NYSE: WLY said its first-quarter fiscal 2027 performance met its internal plan as growth in research publishing and artificial intelligence-related offerings was offset by a difficult comparison with the prior year and continued weakness in learning markets. CEO Matt Kissner said the company generated $14 million in AI revenue during the quarter, while research publishing revenue increased 12%. However, the prior-year quarter included $29 million in AI licensing revenue, creating a significant year-over-year comparison headwind. Learning revenue also declined amid softer professional-market demand and a seasonally smaller academic period. "Nothing in the quarter changes our full-year expectations," Kissner said, adding that Wiley's research content and data assets are increasingly being used in AI-driven scientific and corporate research applications. Research growth and Emerald integration. Research revenue was $293 million, up 4% from the prior-year period. Research Publishing revenue rose 12%, including a $13 million contribution from Emerald Publishing, which Wiley acquired during the quarter. Excluding Emerald, publishing revenue grew about 6%, according to CFO Craig Albright. Research Solutions revenue declined 30%, largely because of the prior-year AI licensing comparison. Softer publishing services and recruiting activity also weighed on the segment, though advertising revenue grew. Research adjusted EBITDA increased 9% to $87 million, and the segment's adjusted EBITDA margin expanded 130 basis points to 29.6%. Albright attributed the improvement to Emerald's contribution and organic cost savings initiatives. Wiley said research publishing demand remained strong, with submissions rising 31% and publishing output increasing 8%. The company also reported customer retention above 99% following its calendar 2026 journal renewal season. The company is integrating Emerald ahead of schedule, management said. Emerald added $5 million of adjusted EBITDA during the quarter at a margin above the research segment average. Wiley expects the acquisition to deliver the full $30 million in targeted cost synergies by its third year, with the bulk of those savings expected in year two. Kissner said Emerald also broadens Wiley's content portfolio in economics, business and finance, supporting its licensing and data analytics strategy. AI revenue pipeline and scientific partnerships. Wiley said it remains on track to exceed $50 million in AI revenue in fiscal 2027 and expects recurring AI revenue to grow two to three times from the prior year. Of the $14 million of AI revenue recognized in the first quarter, $10.5 million came from model-training arrangements and $3.5 million was recurring revenue. The company has contracted another $14 million in AI licensing revenue for recognition across the second and third quarters, with additional agreements under discussion. Albright cautioned that licensing arrangements can be variable or "lumpy," though he said current revenue phasing is similar to last year's pattern after the unusually large first-quarter comparison. Wiley expanded its customer base for subscription knowledge feeds to 23 customers across five verticals: life sciences, healthcare, food and agriculture, materials and chemistry, and financial services. Its Wiley AI Knowledge Nexus licensing service now includes 71 society and publishing partners. During the quarter, Wiley was invited to participate in the U.S. Department of Energy's Genesis Mission, a public-private effort intended to apply AI to scientific and technology challenges. Wiley said it was the sole scientific publisher participating and will provide research intelligence tools to researchers across DOE national laboratories. The company also became a founding data partner in CuspAI's Global Materials Foundry. CuspAI licensed access to Wiley's materials-science content to train its platform, which focuses on materials discovery for semiconductors, clean energy and advanced manufacturing. Wiley also launched its Spectral Analysis API portfolio for corporate and academic laboratories. The offering is designed to deliver chemical reference data into laboratory software workflows. Learning segment remains under pressure. Learning revenue declined 20% to $93 million. Academic revenue fell 20% to $45 million, reflecting $8 million of prior-year AI licensing revenue and lower print sales, partly offset by growth in digital content and courseware. Professional revenue declined 20% to $48 million, including a $5 million prior-year AI licensing comparison, softer consumer demand in retail and weaker corporate demand for assessments. Excluding the AI comparison, learning revenue declined just under 10%, Albright said. Learning adjusted EBITDA was $14 million, with margin falling to 15.1% from 27.4% a year earlier, reflecting lower revenue and product mix. Management said the retail business faced the most difficult comparison of the year following inventory reductions through the Amazon channel in late August of the prior year. Albright said industry retail unit sales declined at the same rate as Wiley's, characterizing the pressure as market-wide. Wiley expects retail inventories to normalize as the year progresses. It also expects courseware and inclusive access offerings to continue growing and assessments performance to improve. The company is concentrating its editorial list on higher-performing titles, investing in digital and inclusive-access channels, and pursuing cost reductions to protect margins. Guidance reaffirmed. Wiley reaffirmed its fiscal 2027 outlook, including organic revenue growth of low-to-mid-single digits and mid-single-digit organic growth in research. Organic growth excludes the expected $78 million contribution from Emerald over 11 months of the fiscal year. * Adjusted EBITDA margin of 26.5% to 27.5%, compared with 26.2% in fiscal 2026. * Adjusted earnings per share of $4.60 to $5.05, compared with $4.19 in fiscal 2026, including roughly $0.10 from Emerald. * Free cash flow of $205 million, up from $195 million in fiscal 2026. First-quarter adjusted EBITDA declined 4% and adjusted EPS fell 10%, partly reflecting higher interest expense associated with the Emerald acquisition. On a GAAP basis, Wiley posted a loss of $0.23 per share, compared with earnings of $0.22 per share a year earlier, primarily due to restructuring charges and acquisition and integration costs. The company raised its dividend for the 33rd consecutive year and returned $33 million to shareholders through dividends and repurchases during the quarter. About John Wiley & Sons (NYSE:WLY). John Wiley & Sons, Inc is a global publishing and educational services company founded in 1807 and headquartered in Hoboken, New Jersey. The company operates through two primary segments: Research & Publishing and Education. Through these segments, Wiley produces a wide range of scholarly journals, books, reference works and digital products for academic, scientific, technical and medical markets, as well as professional development and higher education learning resources. In its Research & Publishing segment, Wiley publishes thousands of peer-reviewed journals and maintains the Wiley Online Library, a leading platform for scientific and scholarly content. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider John Wiley & Sons, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and John Wiley & Sons wasn't on the list. While John Wiley & Sons currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.

Associated Press
Aug 19th, 2026
Wiley launches spectral analysis API portfolio to speed up lab compound identification

Wiley has launched its first spectral analysis API portfolio, allowing laboratories to access its scientific reference databases and analytical tools directly within their own workflows. The APIs enable faster identification and verification of unknown chemical compounds across pharmaceuticals, forensics, environmental science, and other fields. The portfolio includes four core capabilities: spectral database search, spectrum-structure validation, compound classification, and spectra prediction. These tools help labs integrate Wiley's curated spectral data into automated systems, reducing manual effort and analysis time. The APIs address growing demands as sample volumes increase and lab workflows become more software-driven. Unlike fragmented in-house databases, Wiley's solution offers a continuously curated, vendor-neutral foundation supporting multi-technique workflows and regulatory compliance. The launch builds on Wiley's mission to transform knowledge into actionable intelligence for researchers worldwide.

AZoM.com Limited
Aug 12th, 2026
Wiley releases database combining two of the world's most trusted chemical identification resources.

Wiley releases database combining two of the world's most trusted chemical identification resources. Wiley, a global leader in authoritative content and research intelligence, today released the new edition of the Wiley Registry/NIST Mass Spectral Library, a reference database that combines two essential mass spectrometry references in a single, integrated collection, giving scientists the full depth of both to identify unknown chemical compounds. For years, laboratories doing GC-MS analysis have relied on Wiley's renowned Wiley Registry of Mass Spectral Data and the NIST/EPA/NIH EI Mass Spectral Library from the U.S. government's National Institute of Standards and Technology (NIST) to power their analytical workflows. These two respected references are united in this database, one of the most comprehensive resources of its kind. The new 2026 edition updates the collection, adding tens of thousands of newly validated compounds across both libraries and bringing the total to more than 1.2 million electron ionization (EI) mass spectra-unique chemical "signatures" used to identify substances. The Wiley Registry/NIST Mass Spectral Library is part of Wiley's growing portfolio of scientific data and research intelligence solutions, which spans spectral databases, chemistry and materials literature, and analytical tools supporting researchers from discovery through applied outcomes. Wiley's spectral database solutions are trusted by leading pharmaceutical, environmental, and forensic laboratories worldwide, reflecting Wiley's mission to transform knowledge into actionable intelligence that helps researchers make confident, high-stakes decisions. When a scientist runs a sample through a mass spectrometer, the results are only as good as the reference data behind them, By uniting the Wiley Registry and the NIST Library in a single resource, News Medical deliver the breadth, quality, and validation scientists need to identify unknown compounds faster and with confidence." Armughan Rafat, Senior Vice President and Chief AI and Data Analytics Officer, Wiley Available in the most common instrumentation manufacturer formats, the library supports high-confidence analysis across GC-MS workflows. Spectral databases. Spectral databases contain unique molecular "fingerprints" of substances captured through analytical techniques such as infrared (IR), mass spectrometry (MS), nuclear magnetic resonance (NMR), and Raman spectroscopy. By comparing experimental spectra against validated reference data, researchers can accurately identify unknown compounds across a wide range of applications. Be the first to rate this article

Specialty Soya and Grains Alliance
Jul 22nd, 2026
Wiley joins U.S. Department of Energy's Genesis Mission Consortium to advance ai-powered scientific discovery.

Wiley joins U.S. Department of Energy's Genesis Mission Consortium to advance ai-powered scientific discovery. The only scientific publisher in the Consortium, Wiley brings AI-powered research infrastructure, expert-validated workflows, and subject matter expertise to the Mission Wiley today announced its membership in the Genesis Mission Consortium, the public-private partnership supporting the U.S. Department of Energy's (DOE) Genesis Mission, joining organizations including Nvidia, AWS, Microsoft, IBM, and AMD. Wiley is the only scientific publisher among the consortium's members and has been invited to demonstrate its work today at the Genesis Mission Annual Summit in Washington, D.C. The Genesis Mission is a Department of Energy initiative to build the American Science and Security Platform, an AI-driven infrastructure designed to accelerate scientific discovery and harness AI to deliver real-world impact on the most pressing science and technology challenges. Wiley's participation builds on decades of engagement with the DOE and other federal science agencies on research infrastructure. As a consortium member, Wiley plans to make its research intelligence tools available to researchers at all DOE national laboratories and will offer DOE leadership and industry partners an early look at potential applications at today's Summit. Wiley's planned contribution to the Genesis Mission draws on its editorial networks and domain expertise across the sciences and evidence-linked scientific content that supports provenance and reproducibility, alongside operational support to help integrate these capabilities into laboratory environments. "The Genesis Mission is a terrific opportunity for Wiley to apply some of our early breakthrough work in AI and Data Analytics to a program of national importance," said Matthew Kissner, CEO of Wiley. "We are proud to work alongside other members of the Genesis Mission Consortium to help ensure the AI systems shaping science are built on expert-validated workflows and grounded in our rich corpus of authoritative, peer-reviewed content. Accelerating scientific impact requires AI based on trusted evidence - that's the principle behind Wiley's AI platforms, workflows, and partnerships." Founded in 1807, Wiley is the largest U.S. scientific publisher and the world's leading publishing partner to scientific societies, publishing the peer-reviewed research that underpins scientific progress across disciplines and upholding the provenance and credibility of the published scientific record. Wiley's participation in the Genesis Mission Consortium is the latest in a series of global partnerships and initiatives, including collaborations with OpenEvidence, IQVIA, Microsoft, Anthropic, and AWS to bring trusted, peer-reviewed content into leading AI platforms across medicine, life sciences, and research. "Our membership in the Genesis Mission Consortium reflects Wiley's belief that trusted, peer-reviewed content must be at the foundation of any responsible AI infrastructure," said Deirdre Silver, EVP & General Counsel of Wiley. "We're contributing our expertise, the application of trusted scientific knowledge, and the standards and frameworks that will define how science and AI come together to serve the public interest." Leaders and subject matter experts on Wiley's AI & Data Analytics team will participate in Genesis Mission working groups, including those focused on how AI models are validated against scientific evidence and how scientific data is managed. Wiley will also help shape the Consortium's foundational knowledge layer concept, drawing on content and data that are already among the most frequently cited, licensed, and integrated in scientific AI applications worldwide, extending that role into the federal research infrastructure supporting the DOE and its national laboratories. Member News Release submitted by Wiley on 07/22/2026.

Recently Posted Jobs

Sign up to get curated job recommendations

John Wiley & Sons is Hiring for 38 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →